R&D News | pharmaphorum

News

Black and white close up image of an eye

Oculis takes second eye disease therapy into pivotal trials

Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of positive phase 2 data.

News

Dr Ken Macnamara, Trogenix's chief executive

UK's Trogenix raises £70m for cancer immunotherapy platform

Edinburgh-based Trogenix has raised £70m to fund clinical trials of its triple-acting immunotherapies for brain and colorectal cancers.

News

Delayed TNBC readout for Datroway delivers survival benefit

AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.

News

Cidara gets $339m BARDA award for flu prophylactic

Cidara is celebrating a major injection of funding from the US government for its experimental one-shot, universal flu prophylactic CD388.

News

Three more pharmas join OpenFold3 AI consortium

Bristol Myers Squibb, Takeda, and Astex have joined a consortium working on refining the OpenFold structure prediction platform with industry data.

News

Bar graph of gold coins increasing from left to right, with plants growing out the top

Crystalys emerges with $205m, and other biofinancings

Recent biotech financings include big rounds for Crystalys and Star Therapeutics, with Sparrow, Avenzo, and Aerska also raising new funds.

Oculis takes second eye disease therapy into pivotal trials

UK's Trogenix raises £70m for cancer immunotherapy platform

Delayed TNBC readout for Datroway delivers survival benefit

Cidara gets $339m BARDA award for flu prophylactic

Three more pharmas join OpenFold3 AI consortium

Crystalys emerges with $205m, and other biofinancings

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks